- In December 2024, researchers introduced an AI-powered diagnostic tool leveraging the InceptionV3 architecture to classify Polycystic Ovary Syndrome (PCOS) from ultrasound images. This innovative model achieved an impressive 90.52% accuracy, demonstrating the potential of artificial intelligence in advancing medical diagnostics. The study focused on refining AI-driven classification techniques, ensuring precise detection of PCOS while enhancing interpretability through methods like LIME and saliency maps. This breakthrough underscores AI’s transformative role in healthcare, offering reliable and scalable solutions for complex medical conditions
- In December 2024, Gytree launched India’s first PCOS-specific protein supplement, designed to support hormonal balance and overall well-being in women managing Polycystic Ovary Syndrome (PCOS). This innovative formula is enriched with inositol, a key ingredient known for its effectiveness in PCOS management, along with over 16 superfoods that promote metabolic health and energy levels. The supplement reflects a growing shift toward nutraceutical solutions, offering a natural approach to addressing PCOS symptoms. Gytree’s commitment to women’s health continues to drive advancements in wellness products
- In June 2024, Spruce Biosciences announced promising Phase II clinical trial results for Tildacerfont, a CRF1 receptor antagonist, in the treatment of Polycystic Ovary Syndrome (PCOS). The drug targets the hypothalamic-pituitary-adrenal (HPA) axis, offering a novel mechanism of action for PCOS therapy. The POWER study, presented at ENDO 2024, demonstrated significant reductions in dehydroepiandrosterone sulfate (DHEAS) levels and an increase in serum sex hormone-binding globulin (SHBG), suggesting potential benefits in managing hyperandrogenism. Tildacerfont was well-tolerated, with no major safety concerns reported
- In May 2024, May Health, a clinical-stage medical device company, secured $25 million in Series B funding to advance its Ovarian Rebalancing™ therapy for Polycystic Ovary Syndrome (PCOS). The financing round, co-led by Bpifrance and Trill Impact, reflects strong investor confidence in innovative solutions for PCOS management. The company aims to refine its radiofrequency-based ovarian ablation technique, designed to restore natural ovulation in women with PCOS-related infertility. The funding will support ongoing clinical trials, including the REBALANCE Study, which evaluates the therapy’s effectiveness
